Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's true, but how could you know that's what happened?
That's exactly why I said "It was NOT due to the content of the post".
"Do you know why the poster's original message was deleted?"
I do, but this post would be deleted if I revealed it. It was NOT due to the content of the post, which was as follows (unedited):
"Gil Shapira, founder and CEO of NeoLaser has decided to submit the 510(k) application for the StingRay system thru his company NeoLaser in the coming months. His contract with Ehrlich and Bea_Med has become void.
I guess we know why Leo went in to hiding. Now I wonder where that $4,000,000 went."
I don't know about the last two sentences but there was some earlier news that might be worth considering when contemplating the first two. ( https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174862396&txt2find=gil )
"International Healthcare M&A advisory firm MedWorld Advisors is pleased to announce the formation of the MedTech Laser Group via the acquisition of shares of A.R.C Laser GmbH, a German company based in Nuremberg, and of G.N.S. neoLaser Ltd. an Israeli company based in Caesarea (close to Tel Aviv, Israel), by Afinum 9, advised by Afinum Management GmbH, based in Munich, Germany."
"In this partnership, the founders of A.R.C Laser and neoLaser will jointly invest in the formation of this integrated medical laser technology company. As part of the transaction, Afinum acquires a significant majority stake while the founders re-invest in the newly formed entity. "
That doesn't say that "Gil Shapira, founder and CEO of NeoLaser has decided to submit the 510(k) application for the StingRay system thru his company NeoLaser in the coming months", but it does say that he has restructured the ownership of NeoLaser and the press release makes zero mention of BeaMedical or the StingRay system.
"https://afinum.de/en/afinum-releases-the-latest-esg-report-2/"
Maybe this morning's post was BS but GS's new deal may make it worthy of consideration regardless of the motive of the messenger.
Only IPIX's management has the obligation to keep the public informed and in that regard it has been an abject failure.
Is this not true?
"Gil Shapira, founder and CEO of NeoLaser has decided to submit the 510(k) application for the StingRay system thru his company NeoLaser in the coming months. His contract with Ehrlich and Bea_Med has become void."
It's consistent in its wackiness as this was:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174717600
AirplaneGuy includes the following link in his post:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10819233/
That link says that "Brilacidin has previously been tested in over 500 human subjects across multiple clinical indications where it has been shown to be efficacious and well-tolerated [29,30,31,32,33]".
4 of the citations are to 3 Phase 2 trials (ABSSSI, Oral mucositis and Covid) and a Phase 1 trial of a drug delivery system. As far as I know those trials don't establish safety and efficacy, as the quoted statement indicates. Maybe one of the board scientists can clear that up.
The 4th citation is to the Brilacidin page of the IPIX website in which the Company, apparently aware of the impropriety of the assertion, stops short of making it: "Brilacidin has been tested in over 500 human subjects across multiple clinical indications." Full stop.
The latest news from the Company:
Item 1.02 Termination of a Material Definitive Agreement.
On December 1, 2023, Alfasigma S.p.A. (“Alfasigma”) notified Innovation Pharmaceuticals Inc. (the “Company”) of its termination without cause of the Exclusive License Agreement between the parties dated July 18, 2019 (the “License Agreement”), which granted Alfasigma the worldwide right to develop, manufacture and commercialize locally-administered Brilacidin for the treatment of ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS). A description of the License Agreement is set forth in the Current Report on Form 8-K filed by the Company on July 22, 2019 and is incorporated herein by reference. Alfasigma terminated the License Agreement following its decision to discontinue further work under the License Agreement. On December 4, 2023, the parties entered into a mutual release relating to the License Agreement and the Company waived the 60-day notice period for terminations without cause by Alfasigma.
Item 8.01 Other Events.
As previously disclosed, on January 22, 2020, the Company filed a complaint against Cummings Properties, LLC (“Cummings”) in the Superior Court of the Commonwealth of Massachusetts (C.A. No. 20-77CV00101), seeking, among other things, declaratory relief that the lease relating to the Company’s prior principal executive offices terminated in September 2018 rather than automatically extending for an additional five years. On August 29, 2023, the trial for this case commenced, and on January 18, 2024, the Court ruled in favor of Cummings, finding that Cummings is entitled to recover liquidated damages in the amount of $810,251.36, minus the Company’s $77,600 security deposit, plus eighteen percent per annum interest owing since January 17, 2020. The Company intends to appeal the decision.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 31, 2024, Barry Schechter and Zorik Spektor each resigned from the Board of Directors of Innovation Pharmaceuticals Inc. (the “Company”), effective immediately. Their decisions to resign were not the result of any disagreement with the Company on any matter related to the Company’s operations, policies or practices.
Management has failed to comment on any of these items, much less tried to explain them.
Big Pharma knows better than to invest in companies like this. If the lead compound was viable an offer would have been made for it.
"I think the problem has been the OTC which they have stated for awhile."
All OTCMarket's fault? That's hysterical. OTCMarkets isn't holding them captive.
"I do not think the science guys here, including the CEO can hide their geuine excitement and confidence in their programs."
They're doing a fine job of it so far.
"afraid to try because that means the drugs might fail and the whole gig would be up" (incomplete quote)
That has been my feeling for a long time. I think the same theory applies to Diwan's former co-worker (who has just left his Company to rot in the Expert Market). In his case, however, he finally put himself out on a limb. A Phase 2 Covid trial failed and he could no longer hide the lack of effectiveness of his candidate.
"In order to determine if NNVC's NV-387 IND package is good enough for FDA, NNVC needs to actually submit it to them."
Too busy doing the hokey-pokey.
JMO....scientifically unqualified.
That's a mistaken belief. And it's not an "alleged" letter.....I posted the link to the exchanged correspondences here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174910356
Okay so I'm asking. What are the current bid and asked prices for RSPI?
And I'm a little confused about your question so I'm going to re-write it the way I understand it even if my grammar is crappy....hopefully it's the way you meant it:
Are you saying that trades are being made in EM that us retail investors are in the dark about?
For a proper discussion of that I'll refer you here:
https://blog.otcmarkets.com/2023/09/14/the-expert-market-its-larger-role-post-rule-15c2-11/
But a concise answer to your question seems to be "No".
"Trades in Expert Market Securities that are not deemed “Restricted Securities” by FINRA1, are reported and distributed through normal market data distribution channels."
Theoretically we get to see all the trading activity in the "normal market data distribution channels" such as Ihub and OTCMarkets. FWIW Ihub and Y___ daily volume numbers have been identical since entry into the EM.
https://ih.advfn.com/stock-market/USOTC/respirerx-pharmaceuticals-ce-RSPI/historical
Also note that it is my understanding that insiders are prohibited from trading their restricted securities. This fact may be important to those who feel the Expert Market was entered willingly for reasons that I find unclear or just due to their inability to get their filing act together (that's my sense of it).
" Conversely no new money interests can buy or accumulate shares on the EM,"
Sure they can. In fact retail buyers are the only ones having trouble doing that. The market was created to allow "experts" to trade.
Only broker-dealers and professional or sophisticated investors are permitted to view quotations in Expert Market securities hence they are the most likely buyers.
"Pisses you off doesn't it."
What pisses me off? That someone (not you) found a place to trade IPIX shares while paying a commission in excess of twice the share value of the trade? I think it's great and encourage you to avail yourself fully of the opportunity.
"One person out of the approximately 980 board followers found it necessary to demonstrate elementary math skills highlighted with dollop of sarcasm that concluded with a boast about calculator expertise.
Why?"
It's funny that you think dividing is an example of calculator expertise.
No comment regarding the stuff that mattered? That's typical.
"Commission rates as low as $.0009/Share for Stocks.
Doesn't that mean that for every one dollar worth of IPIX shares you buy (or sell) you pay more than two dollars in commissions? "
Aren't you going to ask if there was "No reason given?"? Again.
"So NNVC making official claims that there was no toxicity observed at the tested levels of their drug candidate in public statements is - indeed - something that they should be careful about stating until after FDA review and approval. The FDA emphasized that point in the letter than you cite."
Pretty sure that was an SEC letter, but I'd be very interested to know if the Company has heard directly from the FDA on that score.
"There's an inactivity fee of $30 per quarter to be aware of."
Trader beware! It's gonna cost you 33 cents a day to NOT trade in your Speed Trader account. I expect that would be a major concern to those of you who deal in stocks that change hands for four ten thousandths of a dollar each.
Commission rates as low as $.0009/Share for Stocks.
Doesn't that mean that for every one dollar worth of IPIX shares you buy (or sell) you pay more than two dollars in commissions?
Fortune favors the bold who know their way around a calculator.
Wrong again.
I was skeptical and asked you "can you name a couple?".. You couldn't.
I join you in thanking the poster for providing the information that you could not., although I would question the judgment of anyone using SpeedTrader to buy this particular Company's shares.
No need to be snotty about it.
Aren't you the guy who told us what Form they would have to file to delist even thou they aren't listed? Looks that way.:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174725361
Now you're saying that "OTC 100% does delete non reporting tickers like RSPI" and you're wrong about that, too.
FINRA deletes symbols and then they disappear form the OTCMarkets listings. (BTW, there is no such thing as a"bulletin board" anymore.) The SEC suspends and deregisters stocks.
Stop laughing your ass off and get your entities straight. No wonder these people are ignoring you.
The OTC doesn't delete tickers.
"All stakeholders retain their equity position if such a concept of going private made sense."
But with no means to liquidate their positions.
"The very fact that a reputable regulatory body such as CDSCO allowed us to enter into a clinical trial is indicative that the drug candidate was deemed to be sufficiently safe and effective for humans."
Didn't the FDA say "If it's good enough for Central Drugs Standard Control Organization (“CDSCO”), a regulatory body in India, it's good enough for us?"
I didn't think so.
SCOREBOARD! ------------------------------------------------->>>
The saying is "sound like a broken record".....a broken radio doesn't skip and repeat itself.
Just as some folks here and elsewhere focus on the science I focus on the finances. You can ignore the failure to file and the specious reasons for it at your peril.
Remember, as we know, there are known knowns; there are things we know we know. We also know there are known unknowns; that is to say we know there are some things we do not know. But there are also unknown unknowns—the ones we don't know we don't know.
The truth will come out in the filings....if they ever issue them. Meanwhile, relying on the Rumsfeld theory of investing is all you can do. It ain't great.
"Maybe the remaining convertibles can now just be bought out with cash versus converted into shares."
If only they would produce a filing we'd know how much cash it would take to do that. I'll bet it's more than the $6,362 they had at last report.
"Yeah, that is illogical given they have found minor funding for such things easily in the past from CEO, BOD memebers, wherever, etc. Heck a handful of shareholders on this board could have easily funded the filings."
Your first sentence above is demonstrably true and you're obviously a pretty smart person. I've never been able to understand why such a person would risk their investment money on a management that they know is lying to them.
Can you explain it to me?
Both of these things can't be entirely true:
"RespireRx Pharmaceuticals Inc. (the “Registrant”) was unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the period ended December 31, 2023 (the “Annual Report”) by the April 1, 2024 filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements due to additional time needed for the Board of Directors (acting as the Audit Committee) of the Registrant to complete its review of the Annual Report with the Registrant’s independent registered accounting firm. As a result, the Registrant is still in the process of preparing disclosures and accumulating validating information needed to complete the Annual Report. The Registrant intends to file a complete Annual Report as soon as practicable within the extension period of fifteen calendar days provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended."
https://www.sec.gov/Archives/edgar/data/849636/000149315224012350/formnt10-k.htm
"The SEC filings cannot be done until our auditors are independent. We owe them enough that they are not currently independent."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174687179
You're gonna need some gains to use that against. Which of your portfolio starlets qualify?
Leo's the one who is out of a job. And IPIX is out of money. Open your eyes.
Not out of line, just unnecessary. In the few minutes it 1)took you to ask it and 2)would have taken o_g to answer it you could have found the answer at its source....the court website.
I did just that and while I doubt that you'll 1)trust me or 2)confirm it yourself, the fact is that o_g quoted both docket items verbatim:
08/12/2024 #5 Motion of Appellant to extend date for filing brief and appendix filed for Innovation Pharmaceuticals Inc. by Attorney Daniel Dwyer.
08/13/2024 RE#5: Allowed to 08/21/2024. Notice sent.
That's all there is. There ain't no more.
Your question was half baked anyway ("No reason given?")
It's not clear whether you were asking for IPIX's reason for asking for the extension or the Courts reason for granting it.
Either way there was no reason given.
If there was a reason given you can bet that o_g would have provided it. If you're really concerned you can access the PUBLIC docket, a link to which was provided on these pages 2 months ago.
Too busy?
The SEC had some questions about last year's 10-K and the Qs and As have been posted to Edgar. Several go to the TheraCour relationship and the use of the terms "safe" and "effective" in that filing.
https://www.sec.gov/Archives/edgar/data/1379006/000000000024001724/filename1.pdf
https://www.sec.gov/Archives/edgar/data/1379006/000110465924045423/filename1.htm
https://www.sec.gov/Archives/edgar/data/1379006/000000000024004397/filename1.pdf
https://www.sec.gov/Archives/edgar/data/1379006/000110465924058925/filename1.htm
https://www.sec.gov/Archives/edgar/data/1379006/000000000024005448/filename1.pdf
Contract extensions aren't hard to get if you know the right people:
https://www.sec.gov/Archives/edgar/data/1379006/000110465924087828/0001104659-24-087828-index.htm
Butbutbut "Together, just the three viruses, Influenza, RSV, and COVID, account for over $8 Billion in estimated market size in 2024, growing to an estimated $12 Billion in three years, as calculated by us from various market reports.".
Cue Carl Sagan......
News??? Naaaa. Who would issue it?
Pressed rat and warthog have closed down their shop.
They didn't want to; 'twas all they had got.
Selling atonal apples, amplified heat,
And pressed rat's collection of doglegs and feet.
Sadly, they left, telling no one goodbye.
Pressed rat wore red jodhpurs, warthog a striped tie.
Between them, they carried a three-legged sack,
Went straight round the corner and never came back.
It may be a technicality to you but he wasn't hired by RSPI as you said he was. His Company was contracted to provide his services. There's a difference.
"I think the consultant with the VP title owns Ponto."
Wouldn't surprise me to find that Ponto is a one man show. The LLC address is the same as his home address and Clodfelter signed the latest Ponto fiiing with California as its CEO.
More importantly Ponto was formed by Clodfelter in 2013 and I haven't been able to find any companies for whom they were able to "drive business development". Do you know of any?
Probably reminds you of every other shady drug developer CEO on the planet. Can't swing a dead cat.........
He wasn't hired by the Company.
" Consultant’s duties will be such duties as are normally associated with the position of Senior Vice President of Business Development, working as an independent contractor and not as an employee"
"The monthly invoice will be paid in restricted Common Stock, cash or a pre-agreed combination of cash and Common Stock to Ponto unless assigned in accordance with the terms of the Consulting Agreement."
He work for Ponto, not RespireRx.
Was just about to say "Good Catch" and they dumped out of the Phase.
"The VP hire"
That's not what it was.